Skip to main content
NewslettersWatchlist

Sernova Corp(SVA-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.4200
Day High0.4500
Open:0.4200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Sernova: Bottom 25 Performing Stocks Year-to-Date on TSX (SVA)
The Globe and Mail
Thursday’s analyst upgrades and downgrades
TheNewswire.com
Sernova Provides Positive Clinical and Platform Portfolio Update
Baystreet
U.S. Jobs Reports Due Next Week
The Globe and Mail
Average investors poised to become dissidents as companies face volatile markets
Baystreet
Stocks in play: Sernova Corp.
Baystreet
Stocks in play: Sernova Corp.
Baystreet
Stocks in play: Sernova Corp.
Baystreet
Stocks in play: Sernova Corp.
Business Wire
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
Newswire.ca
Concerned Shareholders of Sernova Corp. Wish to Thank All Shareholders
Baystreet
Stocks in play: Sernova Corp.
Newswire.ca
Concerned Shareholders of Sernova Corp. Stand by their Statements
Newswire.ca
Concerned Shareholders of Sernova Corp. Nominate Two Highly Qualified Directors to the Board
Newswire.ca
Advance Notice Filed with Sernova Corp. for the Nomination of Two Director Nominees
Baystreet
Stocks in play: Sernova Corp.
Business Wire
Sinovac Amends Shareholder Rights Plan
The Globe and Mail
Sernova: Stocks Analysts Recently Downgraded on TSX (SVA)
Baystreet
Stocks in play: Sernova Corp.
Business Wire
SINOVAC Reports Unaudited First Half of 2022 Financial Results
Baystreet
Farewell, 2022
Baystreet
Stocks in play: Sernova Corp.
The Globe and Mail
Sernova: Top 10 Undervalued Biotechnology Industry Stocks (SVA)
The Globe and Mail
Sernova: Top 10 Undervalued Micro Cap Stocks on TSX (SVA)
Baystreet
Stocks in play: Sernova Corp.
Business Wire
SINOVAC Varicella Vaccine Prequalified by WHO
Business Wire
SINOVAC to Showcase Products at CPHI Frankfurt
The Globe and Mail
Sernova: Top 10 Undervalued Healthcare Sector Stocks on TSX (SVA)
Business Wire
SINOVAC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sinovac Biotech Ltd. and Encourages Investors to Contact the Firm
Business Wire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Sinovac Biotech Ltd. (SVA) Investors of Class Action Deadline Against 1Globe Capital LLC and to Actively Participate
PR Newswire
SVA FINAL DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA
Business Wire
SVA FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sinovac Biotech Ltd. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers – SVA

Profile

Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is is a scalable, implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.